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Objective To assess the long-term effects of in utero exposure
to magnesium sulphate for children whose mothers had
pre-eclampsia.
Design Assessment at 18 months of age for children whose
mothers were recruited to the Magpie Trial (recruitment
1998–2001 ISRCTN 86938761), which compared magnesium
sulphate with placebo.
Setting Follow-up of children born at 125 centres in 19 countries
across ﬁve continents.
Population A total of 6922 children were born to women
randomised before delivery at follow-up centres. Of these, 2271
were not included for logistic reasons and 168 were excluded
(101 at a centre where <20% were contacted, 40 whose death
or disability was due to a problem at conception or
embryogenesis and 27 whose parent/s opted out). Therefore,
4483 children were included in follow-up, of whom 3283 (73%)
were contacted.
Methods Assessment by questionnaire, with interview and
neurodevelopmental testing of selected children.
Main outcome measures Death or neurosensory disability at
age of 18 months.
Results Of those allocated magnesium sulphate, 245/1635 (15.0%)
were dead or had neurosensory disability at 18 months compared
with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06,
95% CI 0.90–1.25), and of survivors, 19/1409 (1.3%) had
neurosensory disability at 18 months compared with 27/1442
(1.9%) (RR 0.72, 95% CI 0.40–1.29). There were no substantial
differences in causes of death or in the risk of individual
impairments or disabilities.
Conclusions The lower risk of eclampsia following prophylaxis
with magnesium sulphate was not associated with a clear difference
in the risk of death or disability for children at 18 months.
Keywords Longterm follow-up, magnesium sulphate,
pre-eclampsia, randomised trial.
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Introduction
Pre-eclampsia complicates 2–8% of pregnancies.1 Although
outcome is often good, pre-eclampsia is a major cause of
morbidity and mortality for women and children.2–4 Eclamp-
sia, the occurrence of seizures superimposed on pre-eclampsia,
is rare but associated with even higher morbidity and
mortality,5 particularly in developing countries.3 Magnesium
sulphate is the anticonvulsant of choice for women with
eclampsia.6–8 The Magpie Trial showed that it is also effective
for preventing the ﬁrst eclamptic seizure, without substantive
short-term harmful effects on either mother or baby.9,10
The long-term impact of in utero exposure to magne-
sium sulphate is unclear. Case–control studies have sug-
gested that maternal treatment shortly before birth may
lower the risk of cerebral palsy in surviving very-low-
birthweight infants.11–13 A recent randomised trial found
some evidence to support this view.14 However, trials com-
paring magnesium sulphate with alternative agents for tocol-
ysis of preterm labour show an increase in the risk of fetal,
neonatal or infant death associated with magnesium
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least double), and gave it for considerably longer, than that
in the Magpie Trial.
We contacted women recruited to the Magpie Trial when
their children were 18 months or older. The main objective
was to determine whether magnesium sulphate for pre-
eclampsia affects the child’s chance of surviving without
major neurosensory disability.
Methods
Between 1998 and 2001, 8804 women with pre-eclampsia
during pregnancy or labour were recruited to the Magpie
Trial at 175 hospitals in 33 countries.10 They were randomly
allocated to receive either magnesium sulphate or placebo as
an intravenous loading dose followed by 24 hours of main-
tenance therapy. Treatment details have been reported
elsewhere.10,16
These 8804 women gave birth to 9153 children, 9024 of
whom were included in our analysis of outcome at discharge
from hospital.10 Of these, 2102 babies were never eligible for
follow-up; 127 who were unlikely to have been alive at trial
entry (fetal heart beat not heard at trial entry and macerated
stillbirth within 24 hours) and 1975 born at 50 centres, pre-
dominantly in developing countries, where follow-up was not
thought possible either because reliable contact details were
not available at discharge from hospital or because there was
no local coordinator for the study. Children who ultimately
participated in this follow-up study, having been born to the
cohort of women recruited before delivery at the 125 centres
in 19 countries participating in follow-up, are shown in
Figure 1. All recruited children were included in follow-up
at 92 centres (2145 children) and at least 90% at 106 centres
(3330). Everyone involved in tracing and assessment remained
blind to the allocated treatment. The protocol for follow-up is
available elsewhere.17 Outcome for women18 and narrative
accounts of the collaborators19 are published separately.
Ethics approval and consent
All hospitals secured local research ethics committee approval
before starting recruitment to the main trial. Women were
informed that they might be contacted for follow-up prior
to giving consent for recruitment. Therefore, some centres
did not require that the follow-up study be resubmitted to
an ethics committee. Others required a new submission or
considered the follow-up protocol as an amendment to the
original trial protocol.
How children were assessed
Children were screened using the Ages and Stage Question-
naires (ASQs).20 Thirty questions cover the ﬁve domains:
communication, gross motor, ﬁne motor, problem solving
and personal–social. To pass, the child has to pass all five
domains. An additional section addresses general parental
concerns, and it is not scored. We added two questions about
use of health service resources.17 Up to 24 months, age is
adjusted for gestation at birth. Each questionnaire is valid
for 4 weeks either side of the target age. This was extended
by an additional week for each year of the child’s age.
For centres where the full ASQ was not thought feasible for
cultural or language reasons, we shortened the questionnaires
by selecting the questions considered most likely to predict
severe developmental delay. Three questions were selected in
each of the gross motor, communication and problem solving
domains, together with ﬁve general questions.17 To pass, the
child had to have at least one ‘yes’ in each domain.
Questionnaires were available in English and Spanish. They
were sent by post, administered in clinic (usually a clinic pro-
vided for children within the study) or during a home visit,
or completed over the telephone. If the family could not be
contacted directly, information about whether the child was
‘alive and well’ was collected, whenever possible. The aim was
to assess children when they were at least 18 months, but this
varied depending upon what was feasible.
Children who passed the ASQ for their own age, or for an
older age group, were considered screen negative. Children
who failed the ASQ were considered screen positive. Also
considered screen positive were children whose ASQ was
incomplete and could not be scored and those who passed
the ASQ for children in a younger age group. Screen-positive
children, and a sample of screen-negative children, were
invited for a clinical and neurodevelopmental assessment
using the Bayley Scales of Infant Development (BSID-II)21
or the Grifﬁths Tests,22 or an alternative test if neither was
available. If no test was possible, we relied on clinical
history and examination, including information about non-
neurosensory disability (see below) using the Health Status
Questionnaire.23 The person doing this assessment was usu-
ally aware of whether or not the child had passed the ASQ.
In the UK, the Ofﬁce for National Statistics provided the
date andcause for alldeaths. When surviving UKchildren were
atleast18monthsold,aquestionnairewasalsosenttotheirGP
asking about neurosensory function and general health.
Data review
Data for each child who died, or was thought might have
disability, were reviewed by an independent paediatrician. A
second paediatrician reviewed a 10% random sample of these,
plus any with uncertainty about the diagnosis. Outcome was
determined by consensus. Data for a 20% sample of children
considered screen negative were also reviewed, together with
all those who had a short ASQ only.
Outcome measures
The primary outcome for the follow-up study was the com-
posite measure of death or neurosensory disability at age of
Magpie Trial Follow Up Study Collaborative Group
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alone, each individual measure of neurosensory disability
alone, delayed speech, other disability and contact with health
services.
Deﬁnitions of outcome measures for the children
Death or neurosensory disability at 18 months
of age (primary outcome)
The time point of at least 18 months (corrected for gestation
at birth) provided the best balance between feasibility of
follow up and certainty of diagnosis. Excluded were (a) cases
where death or neurosensory disability was judged to have
had its origin at conception or during embryogenesis, (b)
deaths after 18 months and (c) disability clearly caused by
some event occurring after 18 months. Four children were
classiﬁed as fulﬁlling the criteria for inclusion in the compos-
ite primary outcome because, although only 12–17 months
old when last seen, they were clearly disabled and would be
dead or disabled at 18 months (magnesium sulphate, n =3 ;
placebo, n = 1).
Children were classiﬁed as having neurosensory disability if
they were functionally blind (binocular visual acuity <6/60)
or deaf (severe enough to need a hearing aid), had severe
cerebral palsy (not walking or unlikely to walk unaided by
24 months14) or had a developmental quotient (DQ) <–2 SD.
Children with a DQ <–2 SD were classiﬁed as having deﬁnite
delay, as were children whose developmental progress was less
than that would be expected of an average child half that age.
6922 children
of women randomised before delivery at
centres participating in follow-up study
(125 centres, 19 countries)
2271 children not included in
follow-up study for logistic
reasons*
4483 children
included in follow-up study
Children born to women
allocated magnesium sulphate
Children born to women
allocated placebo
2254 children included 
204 died before discharge
2050 alive at discharge
2229 children included
184 died before discharge 
2045 alive at discharge
619 children with no response 581 children with no response
1635 children analysed 
204 died before discharge
1431 alive at discharge
1648 children analysed
184 died before discharge
1464 alive at discharge
168 children excluded 
101 from centre where <20%
contacted 
40 whose death or disability
was due to a problem at
conception or embryogenesis
27 whose parent/s opted out
* At some centres, children were included in follow-up only if they were born within a pre-specified time frame,
such as the past 1 or 2 years of recruitment (32 centres) or if they lived in a predefined geographic area (1) 
Figure 1. Consort ﬂow for children included in follow up.
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the Denver Developmental Screening Test-2 (DDST-II)24 or
its derivative the Lejarraga and Krupitzky test,25 children were
classed as being ‘likely’ to have developmental delay if prog-
ress in at least one domain was clearly less than that was to be
expected of a child two-thirds that age. Of the 1288 children
who had neurodevelopmental assessment, this was the Lejar-
raga andKrupitzky25 for 743, BSID-II21for 367,DDST-II24 for
49, Grifﬁths22 for 46, Baroda (a derivative of the BSID-II)26
for 14 and other tests for 69.
Other disability
Children with non-neurosensory disability alone (such as
needing continuous supplemental oxygen, breathing support,
renal dialysis, frequent seizures despite treatment and tube or
parenteral feeding)23 were classiﬁed as having ‘other disabil-
ity’. So too were children whose cerebral palsy was judged to
be not severe.
Isolated speech delay
Children with a vocabulary of less than ten words at 24
corrected months but no other developmental problem23
were classiﬁed as having isolated speech delay, as were older
children with equivalent degrees of speech delay.
Power of the study
We anticipated that 2680–3210 children whose mothers were
randomised before delivery would be eligible. We estimated
the composite primary outcome (death or neurosensory dis-
ability) might affect 20–25% of children in the placebo group.
After adjustment for expected losses to follow up, it was antic-
ipated that there would be data on death or disability for
2370–2810 children. This would give 70–80% power (alpha
0.05) to detect a relative difference between the groups of
20% in the primary outcome.17
Statistical analyses
Analyses were based on the groups to which the women and
children had been allocated at trial entry. Centres able to
contact <20% of included families were excluded. Where
appropriate, results are presented as relative risk (RR) with
95% conﬁdence intervals (CI).
Sensitivity analyses for the composite primary outcome
were pre-speciﬁed17 as: excluding children classiﬁed as having
‘likely disability’, including children whose death or neuro-
sensory disability originated during conception or embryo-
genesis, excluding centres where <90% of randomised
children were selected for follow up or where selection was
not based on a time frame and including centres where 80%
or more of the children could not be contacted.
Planned subgroup analyses17 were based on the following:
severity of the mother’s pre-eclampsia at trial entry (severe,
moderate, mild), gestation at birth (£33 completed weeks,
>33 completed weeks), perinatal mortality (PNM) in the
country (high, medium or low)27 and whether the mother
received maintenance therapy of trial treatment by the intra-
muscular or the intravenous route. In addition, a post hoc
Poisson regression was conducted for the primary outcome
adjusting for gestation at birth, whether the mother had an
anticonvulsant before trial entry, PNM in country, route of
maintenance therapy, sex of the baby, multiple pregnancy and
whether admitted to a special care baby unit.
The analysis of children’s death alone included all deaths
and took account of the age at death, using log-rank survival
analysis. Cause of death for the babies was classiﬁed using
standard criteria.28,29
Results
Overall, 125 centres in 19 countries in Africa, Asia, the Amer-
icas, Australia and Europe participated in follow-up. The co-
ordinating centre in Oxford traced children from the 67 UK
centres. Local collaborators traced all other children. Data
collection closed on 31 December 2003. For 27 children, the
parent/s or carers opted out of follow up. Of these, 16 were
‘alive and well’ when contacted. There is no information on
the other 11 children. Also excluded from the analyses were
40 children who died (n = 26) or had disability due to a pro-
blem originating at conception or embryogenesis (14). Two
of these surviving children also had cerebral palsy.
Included in the follow-up study were 4483 children whose
mothers were randomised before birth (magnesium sulphate,
n = 2254; placebo, n = 2229) (Figure 1), of whom 388 (9%)
were stillborn or died before discharge from hospital and 4095
(91%) were alive at discharge. The main substantive differ-
ences between children included in follow-up and those in the
trial overall were that a higher proportion came from low or
middle PNM countries (61% in follow up versus 43% in the
trial overall). Therefore, most of their mothers received the
intravenous maintenance regimen for magnesium sulphate
(63%versus52%).10 Also,fewer children includedinfollow-up
were born before 33 completed weeks (23% versus 27%).
Completeness and review of data
Data for 3283 children (73%) were available for analysis
(magnesium sulphate, n = 1635; placebo, n = 1648) (Fig-
ure 1). For 106 children in the UK, information was from
the GP only. In the UK, 98% of children were contacted.
Outside the UK, 11 centres contacted all included children
and 36 contacted more than half of included children. Data
were available for 57% of children in high PNM countries
(994/1744), 75% in middle PNM countries (1213/1609) and
95% in low PNM countries (1076/1130) (Table 1). Outcome
at discharge from hospital was similar for children included
and for those contacted (Table 1).
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crepancies resolved by discussion. For 73 children, the neuro-
developmental test was overruled as having been incorrectly
applied (magnesium sulphate, n = 34 and placebo, n = 39).
ASQ performance
Of the 2610 children for whom an ASQ was completed, 86%
(2233) had at least one long ASQ and 15% (377) had the short
ASQ only (Table 2). Overall, 636 (24%) were considered
screen positive, of whom 549 (86%) had further assessment
(Table 3). How well the full ASQ distinguished between chil-
dren likely to have or not to have neurosensory disability is
summarised in Table 4. No children passed the ASQ and were
later found to have neurosensory disability among either the
377 screened with the short ASQ only or the 215 screened
with the full ASQ when aged younger than 18 months. Data
were reviewed for 436 children who passed the full ASQ; 122
were reviewed because additional information in the general
questions or elsewhere suggested that they might have disabil-
ity and 314 randomly selected from the remainder, three of
whom had neurosensory disability.
Outcome for the children
Of the children whose mothers were allocated magnesium
sulphate, 245/1635 (15.0%) had the primary outcome of
death or noncongenital neurosensory disability compared
with 233/1648 (14.1%) allocated placebo (RR 1.06, 95% CI
0.90–1.25) (Table 5). This result was consistent across the
pre-speciﬁed subgroups (Figure 2), and it was not substan-
tially altered by any pre-speciﬁed sensitivity analysis (data not
shown) or by adjusting for major prognostic factors (RR 1.07,
95% CI 0.92–1.24) or after excluding children seen only when
younger than 18 months (RR 1.10, 95% CI 0.93–1.29).
There was no signiﬁcant difference between the groups in
the risk of neurosensory disability at 18 months (19/1409
versus 27/1442; RR 0.72, 95% CI 0.40–1.29). Fifteen children
were identified as having cerebral palsy (5 versus 10); this was
severe for 12 (3 versus 9). Two were from a country with high
PNM, seven with middle PNM and six with low PNM.
Of the 2895 children alive at discharge and traced, 44
(1.7%) died after discharge; there were no substantial differ-
ences in causes of death (Table 6). In total, 226/1635 (13.8%)
of children in the magnesium group were stillborn or died
Table 1. Characteristics at trial entry, exposure to magnesium sulphate and outcome at discharge from hospital for children included in follow-up
and those contacted
Children included in follow-up Children contacted
MgSO4, n 5 2254 Placebo, n 5 2229 MgSO4, n 5 1635 Placebo, n 5 1648
Mothers’ characteristics at trial entry
Singleton pregnancy 2094 (93) 2096 (94) 1522 (93) 1554 (94)
Pre-eclampsia
Severe 526 (23) 553 (25) 395 (24) 421 (26)
Moderate 1047 (47) 990 (44) 721 (44) 709 (43)
Mild 691 (30) 686 (31) 519 (32) 518 (31)
Prior anticonvulsant 160 (7) 167 (7) 110 (7) 110 (7)
33 completed weeks of gestation 529 (23) 522 (24) 398 (24) 396 (24)
Intravenous maintenance regimen 1429 (63) 1391 (61) 1142 (70) 1118 (68)
High PNM country 864 (38) 880 (40) 479 (29) 515 (32)
Middle PNM country 823 (37) 786 (35) 617 (38) 596 (36)
Low PNM country 567 (25) 563 (25) 539 (33) 537 (33)
After trial entry
Exposure to MgSO4
None 85 (4) 2216 (99) 70 (4) 1638 (99)
Median (IQR) (g) 14 (5–29) 0 18 (9–29) 0
Time to delivery, median (IQR) (hours) 12 (4–42) 11 (4–39) 12 (4–46) 11 (4–46)
Outcome at discharge from hospital
Born 33 completed weeks 435 (19) 418 (19) 331 (20) 326 (20)
Stillbirth or died before discharge 204 (9) 184 (8) 204 (12) 184 (11)
In special care baby unit* 804 (38) 773 (37) 576 (38) 556 (36)
IQR, interquartile range.
Data are n (%) unless otherwise indicated.
*Liveborn babies only: selected children in MgSO4 group, n 5 2132, and in placebo group, n 5 2108; contacted children in MgSO4 group,
n 5 1513, and in placebo group, n 5 1527.
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95% CI 0.93–1.32) (Table 6).
Of the children for whom we had either a completed ASQ
or information from their GP, more than half were reported
to have attended a clinic since discharge from hospital after
delivery (759/1342 versus 729/1374) and almost one-quarter
had been admitted to hospital (292/1342 versus 301/1374).
There were no substantial differences in these outcomes
between the treatment groups. The most common reason for
hospital admission was respiratory problems (106 versus 109).
Discussion
Our earlier report showed that magnesium sulphate is effective
for prevention of eclampsia.10 Results presented here provide
reassurance aboutsafetyfor thechildreninthelongertermand
are generalisable to both developed and developing countries.
Magnesium sulphate for pre-eclampsia was not associated
with any substantive reduction in survival without neurosen-
sory disability for the children exposed while in utero.
When the Magpie Trial was designed, follow-up was
planned in the UK only. Once it became clear that more than
80% of recruitment was from developing countries, it seemed
imperative to at least try to contact a sample of these women
and children. Although 50 centres were unable to participate
in follow-up, this could not have introduced bias into the
assessment of outcome, as randomisation had been stratiﬁed
by centre. For the 125 centres that did participate in follow-
up, 74% included follow up of all children recruited and 85%
included at least 90% of children. The decision about who was
included in follow-up was made at the start of the study, blind
Table 2. For children alive at discharge from hospital and traced:
information from tracing and screening
MgSO4,
n 5 1431
Placebo,
n 5 1464
ASQs completed 1283 (90) 1327 (91)
At least one full ASQ 1101 1132
Short ASQ only 182 195
No ASQ 148 (10) 137 (9)
Information from GP
questionnaire (UK)
59 47
‘Alive and well’ only information 63 63
Child dead 24 25
Paediatric assessment
but no ASQ
22
ASQ scoring
Complete 1186 (83) 1186 (81)
Ratio score for full ASQ 87 (6) 128 (9)
Incomplete and unable to score 10 (1) 13 (1)
When ASQ completed
Within correct time frame* 1070 (75) 1049 (72)
Outside correct time frame 213 (15) 278 (19)
ASQ for an older age group 131 162
ASQ for a younger age group 82 116
Failed ASQ 240 (17) 226 (16)
ASQ for correct age or an
older age group
229 209
ASQ for a younger child 11 17
Data are n (%).
*Based on Magpie Trial time frame.17
Table 3. For children alive at discharge from hospital: further
assessment after tracing and screening
MgSO4,
n 5 1431
Placebo,
n 5 1464
Outcome determined without
further assessment
25 (2) 26 (2)
Known severe neurosensory disability 1 1
Child died after discharge 24 25
Screen-positive children* 311 (22) 325 (22)
Clinical assessment 1
neurodevelopmental test
217 215
Clinical assessment alone 51 66
ASQ only, no further assessment 43 44
Screening to assessment (days),
median (IQR)
5 (0–55) 3 (0–52)
Screen-negative children** 972 (69) 1002 (68)
Clinical assessment 1
neurodevelopmental test
413 440
Clinical assessment alone 245 241
ASQ only, no further assessment 314 321
Screening to assessment (days):
median (IQR)
0 (0–6) 0 (0–4)
No ASQ but had
neurodevelopmental test
21
Child’s age at assessment or when
known to be ‘alive and well’
,12 months 20 31
12–17 months 195 135
18–23 months 219 259
24 months 914 967
Data from GP only 59 47
Data reviewed by paediatrician† 685 (48) 739 (50)
Considered screen-positive 311 326
Considered screen-negative 355 397
Died after discharge 24 25
No ASQ 19 16
IQR, interquartile range.
Data are n (%) unless otherwise indicated.
*Children who failed the ASQ regardless of whether or not within
the correct time frame, or who passed it but the ASQ was for a
younger age group or whose ASQ could not be scored.
**Children who passed the ASQ for their correct age or for an older
age group.
†Data also reviewed for the 388 children who died before
discharge.
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only tried to contact a proportion of children was that many
of those born early in the trial would have changed address,
possibly several times, and so would be impossible to trace.
Hence, in these centres, children were only included in follow
up if they were born after a pre-speciﬁed date. At one centre,
an additional factor was that it was unsafe to visit certain
geographic areas, so those with a discharge address within
these pre-speciﬁed areas were not included. It is implausible
that these factors could have been related to outcome, and as
they are likely to be equally distributed between the treatment
groups because of the randomisation, it is unlikely that they
introduced any bias.
Having provided reassurance that there was no potential
bias between the groups in the way children were selected for
inclusion in follow-up, our pragmatic philosophy was that
any information about outcome was better than none. This
approach enabled us to trace families and assess children in
situations where follow-up had previously been thought
impossible. We are not aware of other perinatal trials that
have conducted follow-up in a comparable range of countries
and settings. Restricting the study to centres able to guarantee
that a high proportion of children could be traced would
have excluded most low-income countries. Overall, 73% of
included children were contacted, which is a remarkable
achievement. In many countries, there was a strong impres-
sion that women valued this continued interest in the welfare
of their child. The chief exception was some rural communi-
ties, where strangers visiting a remote village might be
regarded with suspicion.
A key challenge was to identify an appropriate and simple
toolforscreeninglargenumbersofyoungchildrenoverawide
age range and in a variety of settings and countries. The ASQ20
seemed to meet these criteria. Although it is user friendly,
with pictures and clear text, each questionnaire is three pages.
As this was initially thought to be rather long for some com-
munities, especially those who werenon-English speakingand
predominantly rural, we shortened it to one page. In practice,
many centres found administering the full ASQ less problem-
atic than anticipated. Uptake of the short ASQ was therefore
lower than expected.
The use of a variety of tools for neurodevelopmental assess-
ment and that it was not possible for all children to have a full
assessment were limitations of this study. Also, this follow-up
has less power than the original trial as it was not feasible to
include all children randomised, those included tended to be
at lower risk of adverse outcome and it was harder to contact
families in high PNM countries. These losses to follow-up do
Table 4. For children with a full ASQ: screening result and whether
the child had neurosensory disability
ASQ outcome Neurosensory disability
Yes* No Total
Failed** 42 538 580
Passed 3*** 433 436
Total 45 971 1116
*Includes likely neurosensory disability.
**Includes 129 who passed the ASQ for a younger age group, 26
who failed the ASQ for a younger age group and 20 whose ASQ
could not be scored. Excluding those with an ASQ for a younger age
group, the negative predictive value is 433/436 5 99.3%.
***All were 18 months when screened; two passed scored section
of the ASQ, but there was concern about hearing or speech in
general section.
Table 5. For all selected children: death or neurosensory disability
MgSO4,
n 5 1635
Placebo,
n 5 1648
Death after randomisation and
• 18 months
226 (13.8) 206 (12.5)
Stillbirth or died before discharge 204 184
Died after discharge 22 22
Neurosensory disability* 13 (0.8) 19 (1.2)
Blind 3 3
Deaf 2 1
Severe cerebral palsy 3 9
Developmental delay 11 15
Likely neurosensory disability 6 (0.4) 8 (0.5)
Blind — —
Deaf 1 —
Severe cerebral palsy — —
Developmental delay 5 8
Death or neurosensory disability at 18 months
For all contacted children 245 (15.0) 233 (14.1)
For children followed until
either they developed
the primary outcome or
at least 18 months old**
245 (17.2) 233 (15.7)
Other signiﬁcant disability 3 (0.2) 5 (0.3)
Other cerebral palsy not
included above
21
Other disability — 3***
Isolated speech delay 23 (1.4) 29 (1.8)
Simple, probably transient 22 27
Features suggestive of autism 1 2
Data are n (%).
*Some children had more than one disability. One child with known
neurosensory disability did not have an ASQ.
**MgSO4, n 5 1421; placebo, n 5 1480.
***One child had each of the following: chronic oxygen dependency
at 18 months following viral chest infection at 3 months, apraxia,
Erbs palsy.
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results are relatively consistent across countries with differing
completeness of follow-up. In a blinded trial such as ours, it
is unlikely that not being able to trace 27% of children after
discharge would introduce appreciable bias in the conclu-
sions, as the reasons for failure to contact them will have been
equally true of children in both arms of the study. As those
who were followed-up had been randomly exposed to mag-
nesium sulphate, these data still allow an unbiased assessment
of the treatment effect of antenatal magnesium sulphate on
longer term outcomes. Moreover, the total numbers eventu-
ally followed, 2895 survivors from 3283 enrolled, are large
relative to other antenatal trials and still allow power to detect
uncommon adverse outcomes. By comparison, the Cochrane
review of antenatal steroid therapy,30 the most obvious exam-
ple of an antenatal intervention that has improved outcome
for preterm infants, comprises data on only 3517 fetuses
exposed, of whom 3184 survived and on whom long-term
outcome data are reported for just 778 children.
Magnesium sulphate given as neuroprotection to women
at risk of preterm birth before 30 weeks of gestation has been
evaluated in one previous trial;14 there was a tendency to
a lower risk of death or cerebral palsy at 2 years if the mothers
were allocated magnesium sulphate rather than placebo (RR
0.83, 95% CI 0.66–1.03). Nearly 8%of surviving babies in that
study had cerebral palsy; only 17 surviving children were
identified as having cerebral palsy in the present study, and
in two of these, the problem was thought to have arisen dur-
ing conception or embryogenesis. However, 10 of the other
15 children were among those whose mothers were allocated
placebo (Table 5). The numbers involved are small, and this
imbalance could have arisen by chance, but the trend is in the
same direction as in the earlier trial.14 In our study, only one
baby with cerebral palsy and 2.3% of all the babies were born
before 30 weeks of gestation.
Relative risk
Favours MgSO4 Favours placebo
0.5 1 1.5 2
Relative risk
(95% CI)
No. of events
Placebo
Gestation at birth
≤33 completed weeks 1.03 (0.87–1.22) 152/331 145/326
Severity of pre-eclampsia at trial entry
Severe 0.97 (0.74–1.27)
Moderate 1.08 (0.85–1.37)
Mild 1.27 (0.82–1.97)
82/395
121/721
42/519
90/421
110/709
33/518
MgSO4
Test of 
interaction
P = 0.6
P = 0.9
Centre*
Intramuscular maintenance regimen (23 centres) 1.15 (0.94–1.41) 138/493 129/530
Intravenous maintenance regimen (99 centres) 1.01 (0.78–1.30) 107/1142 104/1118
Country
High PNM 1.08 (0.89–1.31)
Middle PNM 1.28 (0.91–1.80)
Low PNM 0.83 (0.51–1.33)
147/479
69/617
29/539
146/515
52/596
35/537
>33 completed weeks 1.04 (0.78–1.39) 89/1294 87/1318
Overall 1.06 (0.90–1.25) 245/1635 233/1648
P = 0.3
P = 0.4
PNM, perinatal mortality.
* Excludes three centres: at two, no women were recruited before delivery; hence no children born to women randomised before birth; at
another, all data excluded, as less than 20% of included children contacted.
Figure 2. Effects of treatment on death or neurosensory disability at the age of 18 months: subgroup analyses.
Table 6. For all children selected and traced: death and cause of death
MgSO4,
n 5 1635
Placebo,
n 5 1648
Included in primary outcome
(died • 18 months)
226 (13.8) 206 (12.5)
Stillbirth 122 121
Liveborn
Died before discharge 82 63
Died after discharge 22 22
Not included in primary outcome
Died .18 months 2 3
Total deaths 228 (13.9) 209 (12.7)
Cause of death
Infection before/during birth 2 1
Antepartum stillbirth* 122 120
Preterm birth 56 48
Intrapartum asphyxia/trauma 20 13
Infection after birth 15 14
External agent after birth 1 2
Sudden infant death 1 1
Unclassiﬁable 11 10
Data are n (%).
*Does not include infection acquired before or during birth.
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Magnesium sulphate for women with pre-eclampsia more
than halves the risk of eclampsia (RR 0.42, 95% CI 0.29–
0.60) and probably reduces the risk of maternal death
before discharge from hospital (RR 0.55, 95% CI 0.26–
1.14) compared with placebo. No substantive harmful
effects were apparent in the short term, for either mother
or baby. Exposure to magnesium sulphate while in utero
was not associated with a clear difference in the risk of
death or disability for children at 18 months. These data
provide reasonable reassurance about the long-term safety
of magnesium sulphate for the children, at the dosage used
in our study.
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